免疫系统
信使核糖核酸
免疫学
生物
细胞生物学
基因
遗传学
作者
Jia Shi,Mengwen Huang,Zi-Dong Lu,Xiao‐Jiao Du,Song Shen,Cong‐Fei Xu,Jun Wang
标识
DOI:10.1016/j.jconrel.2022.03.033
摘要
Abnormal immune cell functions are commonly related to various diseases, including cancer, autoimmune diseases, and infectious diseases. Messenger RNA (mRNA)-based therapy can regulate the functions of immune cells or assign new functions to immune cells, thereby generating therapeutic immune responses to treat these diseases. However, mRNA is unstable in physiological environments and can hardly enter the cytoplasm of target cells; thus, effective mRNA delivery systems are critical for developing mRNA therapy. The two mRNA vaccines of Pfizer-BioNTech and Moderna have demonstrated that lipid nanoparticles (LNPs) can deliver mRNA into dendritic cells (DCs) to induce immunization against severe acute respiratory syndrome coronavirus 2, which opened the floodgates to the development of mRNA therapy. Apart from DCs, other immune cells are promising targets for mRNA therapy. This review summarized the barriers to mRNA delivery and advances in mRNA delivery for regulating the functions of different immune cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI